Clinical trial
A Phase IV, Randomised, Multicentre, Efficacy and Safety Study Examining the Effect of Induction Dosing With the Combination of Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Infected With Hepatitis C Genotype 1
NCT00192647 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IV, Randomised, Multicentre, Efficacy and Safety Study Examining the Effect of Induction Dosing With the Combination of Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Infected With Hepatitis C Genotype 1
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- August 31, 2004
- Completion date
- March 31, 2009
- Enrollment
- 896 (actual)
- Sites
- 51
Conditions
As the registry lists them; a condition with its own page is linked.